Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Revealing liver micrometastases in vivo using ultra-high definition MRI

Project description

Unveiling the hidden spread of cancer

Most cancer deaths occur because of metastases. These are the tiny, often undetectable cells that spread to other organs. Detecting these early, especially in the liver, could transform treatment and survival. However, current imaging tools like MRI lack the sensitivity to spot them. With this in mind, the ERC-funded MicroMetSCAN project aims to build on advances in MRI technology. It will develop ultra-high-resolution methods capable of revealing micrometastases long before they grow into larger tumours. By refining contrast and analysing tissue changes, MicroMetSCAN will improve early cancer diagnosis and shed light on how metastases form and evolve.

Objective

Over 90% of cancer-related deaths are caused by metastases. A major obstacle for accurate patient stratification, development of new treatments against metastases and thorough biological understanding is our inability to detect early-stage micrometastases (µMets). The liver is one of the first and most common sites for metastases, particularly in gastrointestinal tract tumours. Thus, early detection of liver metastases is an urgent need in cancer diagnosis for many patients. Present image-based diagnostic methods, including state-of-the-art Magnetic Resonance Imaging (MRI), cannot detect µMets due to major limitations in current image contrast and resolution, as well as a lack of understanding of liver tissue changes during the metastatic process.

MicroMetSCAN proposes a paradigm-shifting MRI approach based on highly promising preliminary results that leverages recent progress in MRI acquisition, denoising and contrast generation, to reach the breakthrough of exquisite sensitivity and specificity required to detect and characterise μMets in the liver and provide new insights about metastases-related tissue microenvironment dynamics. To achieve its overarching goal, my proposal consists of four objectives: 1) developing new ultra-high resolution MRI methods targeting robust µMets detection, 2) tailoring the specificity of contrasts towards μMet environments, 3) unravelling the transformations from µMets to full metastases in animal models, yielding critical insights into tumour growth patterns, and 4) translating the new MRI approach to the clinic in a prospective clinical study.

MicroMetSCAN will significantly advance the state-of-the-art in cancer imaging, to enable precision diagnosis and treatment planning, with wide-reaching applicability, especially benefitting small lesion detection. Furthermore, it will unveil important biological insights on the progression of metastasis, guiding future therapeutic strategies for better prognosis and outcomes.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-STG

See all projects funded under this call

Host institution

KING'S COLLEGE LONDON
Net EU contribution
€ 1 998 456,00
Address
STRAND
WC2R 2LS London
United Kingdom
Region
London Inner London — West Westminster
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 998 456,00

Beneficiaries (1)